Jay D. Kranzler
Chairman of the BoardDr. Jay D. Kranzler, M.D. Ph.D. serves as Chief Executive Officer and Chairman of Urica v, Inc. He serves as Chairman of the Board Avenue Therapeutics, Inc. since March 07, 2023. He serves as the President and Chief Executive Officer of Karuna Pharmaceuticals. Dr. Kranzler serves as Chief Executive Officer of Regenovation, Inc. He is Member of Clinical Advisory Board of Owaves, Inc. from 2025. He served as Member of Clinical and Scientific Advisory Board at Athira Pharma, Inc. He is also an Entrepreneur-in-Residence at Puretech Ventures. He is Chairman and Chief Executive Officer of Urica Therapeutics, a clinical-stage biopharmaceutical company since October 2022. Dr. Kranzler has management experience, his service as an executive of biopharmaceutical companies and his knowledge of business and industry. From January 1989 to August 1995, Dr. Kranzler served as the President and Chief Executive Officer of Cytel Corporation. He is also currently a Board Member of multiple private companies, including Baergic Bio Inc. Navitas Pharma, Kore Therapeutics Ltd. and OnTrack Therapeutics Ltd. each focused on the research and experimental development of therapeutics. Dr. Kranzler served as a Director of Cytel Corporation from January 1989 to August 1995. From 1985 to January 1989, he served as a Management Consultant at McKinsey & Company. He served as the Chairman Emeritus of Cypress Bioscience, Inc. since January 2011 and also served as its Chief Executive Officer from December 1995 to January 2011, Chairman from April 1998 to January 2011, Vice Chairman since December 1995 and Director until January 2011. He serves as Chairman of MSI Methylation Sciences, Inc. He serves as an Executive in Residence at UCSD Rudy School of Management. Dr. Kranzler serves as Director of Avenue Therapeutics, Inc. since May 12, 2022 and served as its Independent Director since February 2017 until May 12, 2022. He has been an Adjunct Member of the Research Institute of Scripps Clinic since January 1989. He serves as a Director of Regenovation, Inc. He serves as a Member of Executive Advisory Board at NYU Innovation Venture Fund. He serves as an Adjunct Professor and Entrepreneur-in-Residence at the NYU Stern School of Business. Dr. Kranzler developed a fibromyalgia syndrome drug from concept to market, including the design of clinical trials and regulatory path through Phase III trials and FDA approval. Dr. Kranzler is a recipient of the Award for Innovation from the International Society of CNS Drug Development. Dr. Kranzler has been a Founder, Chief Executive Officer, Board Member and Advisor to leading life science companies. He is Acting as Executive Chairman of Perception Neuroscience, a company that he co-founded, a regenerative medicine company and is a Board Member of Pastorus and ImmunoBrain Checkpoint, all companies focused on developing therapeutics for psychiatric or neurological disorders. Dr. Kranzler was also Vice President, Head of Worldwide External R&D Innovation and Strategic Investments at Pfizer. During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics and is the inventor on over 30 patents. Dr. Kranzler graduated from Yale University School of Medicine with M.D. and Ph.D. degrees with a focus in psychopharmacology.
Positions
- Company NameAvenue Therapeutics, Inc.Stock CodeATXIPositionChairman of the Board
